Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review

<table>Response-monitoring and prognostic biomarkers for SLIT [<a href="/journals/ja/2012/381737/#B36">36</a>].  (a) Total scores from a QOL questionnaire are plotted for the SLIT group (All), a subgroup with increased antigen-specific Treg in the SLIT group (Inc), a subgroup with decreased antigen-specific Treg in the SLIT group (Dec), and the placebo (Plc) group after 2 years of treatment.  **<svg height="11.375" id="M22" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 58.712502 11.375" width="58.712502" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><use xlink:href="#x1D443"></use></g><g transform="matrix(.017,-0,0,-.017,15.582,11.112)"><use xlink:href="#x3C"></use></g><g transform="matrix(.017,-0,0,-.017,30.286,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,38.446,11.112)"><use xlink:href="#x2E"></use></g><g transform="matrix(.017,-0,0,-.017,42.321,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,50.481,11.112)"><path d="M384 0h-275v27q67 5 81.5 18.5t14.5 68.5v385q0 38 -7.5 47.5t-40.5 10.5l-48 2v24q85 15 178 52v-521q0 -55 14.5 -68.5t82.5 -18.5v-27z" id="x31"></path></g>
</svg> (Mann-Whitney <svg height="11.4625" id="M23" style="vertical-align:-0.23206pt" version="1.1" viewbox="0 0 13.1 11.4625" width="13.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><path d="M751 650l-6 -28q-53 -1 -69 -12.5t-24 -38.5q-23 -85 -43 -192l-13 -69q-34 -181 -130 -262q-79 -65 -185 -65t-171 57q-87 77 -54 258l42 232q12 58 0.5 73t-75.5 19l8 28h263l-6 -28q-63 -5 -78 -18t-26 -74l-41 -226q-25 -135 22 -201t139 -66q99 0 161.5 68t91.5 217
l11 57q28 149 28 193q0 28 -19 38t-79 12l6 28h247z" id="x1D448"></path></g>
</svg>-test).  (b) SMSs in the peak pollen season for patients with low and high sIgE/tIgE ratios in the SLIT group (Act.).  *<svg height="11.375" id="M24" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 58.712502 11.375" width="58.712502" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><use xlink:href="#x1D443"></use></g><g transform="matrix(.017,-0,0,-.017,15.582,11.112)"><use xlink:href="#x3C"></use></g><g transform="matrix(.017,-0,0,-.017,30.286,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,38.446,11.112)"><use xlink:href="#x2E"></use></g><g transform="matrix(.017,-0,0,-.017,42.321,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,50.481,11.112)"><use xlink:href="#x35"></use></g>
</svg>.  (c) Correlation between SMSs after 2 years of SLIT treatment and sIgE/tIgE ratios before treatment in the SLIT (Act, closed diamonds) and placebo (Plc, open diamonds) groups.  Statistical data were obtained with Spearman correlation analysis.  N.S.: not significant.</table>

Journal of Allergy

fig2

Figure 2

Figure 2: Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review 